Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Dezember 2014 09:00 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors

FLEMINGTON, N.J., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics,...
09. Dezember 2014 09:00 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014

Abstract #5567 Poster #P5-02-13 Poster Session 5 Friday, December 12; 5:00 – 7:00 p.m. CT Track: Diagnostic Pathology,...
04. Dezember 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors

FLEMINGTON, N.J., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today...
24. November 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics to Present at LD Micro Conference 2014

FLEMINGTON, N.J., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
14. November 2014 16:34 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Reports Third Quarter 2014 Financial and Business Update

FLEMINGTON, N.J., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
29. Oktober 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics' Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference

FLEMINGTON, N.J., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
27. Oktober 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage

FLEMINGTON, N.J., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
23. Oktober 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics to Present Encouraging Data From Ongoing Phase I/II Trial Evaluating Onapristone in CRPC at 21st Annual PCF Scientific Retreat

FLEMINGTON, N.J., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
30. September 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics to Present at the 13th Annual BIO Investor Forum

FLEMINGTON, N.J., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
18. September 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics' Executive Selected to Chair World CDx Boston 2014

FLEMINGTON, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Vorherige Seite

Nächste Seite